After hours of discussion and a request to revise the question they were being asked, a key federal advisory committee on Friday recommended a third dose of the Pfizer-BioNTech COVID-19 vaccine six months after full vaccination for people aged 65 and older and those at high risk of severe COVID-19.
The initial question, posed by Pfizer, would have made the booster available to everyone aged 16 and up.
There isn’t yet sufficient evidence to show boosters for people under 65 are necessary, said members of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee.
Those at high risk would include health care workers, first responders and people likely to be exposed to the virus at work, committee members said.
Members said getting it right, and waiting to follow the science, were important factors.
News Source: Hindustan Times
